Objectives The aim of this study was to compare the perception, confidence, hesitancy and acceptance rate of various COVID-19 vaccine types among healthcare workers (HCWs) in Saudi Arabia, a nation with Middle East respiratory syndrome coronavirus experience.
Design National cross-sectional, pilot-validated questionnaire.
Setting Online, self-administered questionnaire among HCWs.
Participants A total of 2007 HCWs working in the Kingdom of Saudi Arabia participated; 1512 (75.3%) participants completed the survey and were included in the analysis.
Intervention Data were collected through an online survey sent to HCWs during 1–15 November 2020. The main outcome measure was HCW acceptance of COVID-19 candidate vaccines. The associated factors of vaccination acceptance were identified through a logistic regression analysis and via measurement of the level of anxiety, using the Generalised Anxiety Disorder 7 scale.
Results Among the 1512 HCWs who were included, 62.4% were women, 70.3% were between 21 and 40 years of age, and the majority (62.2%) were from tertiary hospitals. In addition, 59.5% reported knowing about at least one vaccine; 24.4% of the participants were sure about their willingness to receive the ChAdOx1 nCoV-19 vaccine, and 20.9% were willing to receive the RNA BNT162b2 vaccine. However, 18.3% reported that they would refuse to receive the Ad5-vectored vaccine, and 17.9% would refuse the Gam-COVID-Vac vaccine. Factors that influenced the differential readiness of HCWs included their perceptions of the vaccine’s efficiency in preventing the infection (33%), their personal preferences (29%) and the vaccine’s manufacturing country (28.6%).
Conclusions Awareness by HCWs of the several COVID-19 candidate vaccines could improve their perceptions and acceptance of vaccination. Reliable sources on vaccine efficiency could improve vaccine uptake, so healthcare authorities should use reliable information to decrease vaccine hesitancy among frontline healthcare providers.
- anxiety disorders
Data availability statement
Data are available upon reasonable request.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Strengths and limitations of this study
The research is among the first studies to explore the perception, confidence, hesitancy and acceptance rates of various COVID-19 vaccine types among healthcare workers (HCWs).
This is a national, cross-sectional survey among HCWs.
The press release on the efficacy of the BNT162b2 vaccine coincided with ongoing data collection about the HCWs’ willingness to vaccinate.
Being a self-reported and survey-based study highlights that observational studies on the HCWs’ actual acceptance of various COVID-19 vaccines are warranted in the nearest future.
The convenience sample could limit the generalisability; therefore, further research is warranted.
The COVID-19 pandemic has severely disrupted normal societal and economic activities worldwide and is expected to continue imposing strains and burden on health systems in most of countries. Globally, the COVID-19 pandemic remains out of control.1 The existing measures to control COVID-19 are detrimental to the global economy2 and result in significant impairment in physical and psychological well-being.3 To keep COVID-19 under control, there is a strong need for an effective vaccine. Without COVID-19 vaccination, healthcare workers (HCWs) will likely be at risk and are likely to serve as reservoir inside health institutes, which would undermine efforts to end the pandemic. According to the WHO, there are 56 and 166 candidate vaccines in clinical and preclinical evaluation by 17 December 2020.4 These include JNJ-78436735, an adenovirus vaccine (Ad26.COV2.S);5 6 mRNA-1273, an mRNA vaccine;7 AZD1222, an adenovirus vaccine (ChAdOx1 nCoV-19);8 BNT162b1, an mRNA vaccine;9 NVX-CoV2373, a full-length recombinant SARS-CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M;10 Ad5-nCoV, an adenovirus vaccine.11–14 Encouraging news is that several vaccines had been released and many are in phase III clinical trials and showing promising effectiveness.15 As some safe and efficacious vaccines became available, policymakers need to ensure a successful large-scale uptake of COVID-19 vaccines to achieve community immunisation. However, the success of COVID-19 vaccination programmes will largely depend on people’s acceptance of the vaccine. A recent global survey suggested that nearly 30% of participants would be hesitated to take a COVID-19 vaccine when it is available.16 A systematic review on acceptance of a COVID-19 vaccine based on nationally representative surveys in 20 nations indicates that vaccine acceptance rate in most nations would not reach 67% that is necessary for achieving population immunity.17 Mathematic modelling suggested that if a COVID-19 vaccine efficacy was 80%, the coverage must achieve at least 75% to extinguish the ongoing pandemic.18 Therefore, a timely understanding of community responses to the forthcoming COVID-19 vaccines would be important for policymaking and service planning.
Extant literature has explored vaccine acceptance and identified a few demographic and psychosocial correlates such as gender, age, trust in research, knowledge, and concerns about the novel vaccine, as well as people’s judgement and perceptions regarding risk of COVID-19.19–21 Risk exposure to the disease is one of several essential issues that directly shape people’s assessment to their vulnerability and risk. Even being weaponed with personal protective equipment, healthcare providers and other essential workers are considered to have high risk exposures to COVID-19 and given priority in vaccine allocations. Several studies suggest that being an HCW or being involved in the care of patients with COVID-19 is positively associated with COVID-19 vaccine acceptance.22–24
The lessons learnt from previous infectious disease pandemics and outbreaks, including SARS, H1N1, Middle East respiratory syndrome coronavirus (MERS-CoV) and Ebola demonstrate the important role that health information has on disease control and vaccine acceptance.25 Source of health information can affect the manner and frequency of the utilisation of such information. The degree to which the information source is trusted can have a remarkable impact on the acceptance of information.26 If HCWs distrust the source, they will doubt the information regarding different COVID-19 vaccines, and this doubt will in turn shape their attitudes, perceptions and potential actions they take toward various COVID-19 vaccines.
The Kingdom of Saudi Arabia (KSA) is one of the top 30 countries with the highest reported COVID-19 cases: 360 690 laboratory-confirmed cases and 6101 deaths as of 19 December 2020.27 Acceptance of a potential COVID-19 vaccine assessed among HCWs in KSA in a survey of 2007 participants showed an acceptance rate of 70%,28 which is slightly higher than the acceptance rate found in public survey among 992 participants of general population (acceptance rate of 65%).29 Perception, confidence, and hesitancy for various COVID-19 vaccines in the context of emerging viral infections and pandemics and manufacturing company and the different sources of information are principal factors in assessing vaccine acceptance of various types. To the best of our knowledge, none of published surveys specifically targeted and compared HCWs’ perception, confidence and hesitancy toward different types of COVID-19 candidate vaccines. While our previous research showed that most (70%) HCWs are willing to receive COVID-19 vaccines once available,28 we aimed in this study to compare the perception, confidence, hesitancy and acceptance rate of various COVID-19 vaccine types among HCWs.
This study was a national cross-sectional survey among HCWs in Saudi Arabia during COVID-19 pandemic. Data were collected during 4–14 November 2020. At the time of data collection, at least seven COVID-19 vaccine candidates had been reported in the scientific literature. HCWs were screened for their awareness of any of the seven published vaccines.28 Participants were invited using a convenience sampling technique. We used several social media platforms and email lists to recruit participants for direct invitation. The survey was a pilot-validated, self-administered questionnaire that was sent to HCWs online through SurveyMonkey, a platform that allows researchers to deploy and analyse surveys via the internet.30 This was an English questionnaire (as invited participants were multinational and all were English speakers) (online supplemental appendix 1)31 with modifications and additions related to the potential COVID-19 vaccine.
The questions included the demographic characteristics of respondents (job category, age, sex, years of clinical experience and work area), and any previous exposure to MERS-CoV or to patients with COVID-19 (either suspected or confirmed). We assessed the following outcomes related to the seven COVID-19 vaccine candidates that had been reported in the scientific literature: knowledge, perceived awareness and readiness to receive each type of COVID-19 vaccine candidate. In addition, we assessed factors affecting respondents’ readiness to receive various COVID-19 vaccine candidates and the HCW’s sources of information about COVID-19 vaccines.
Before participation, the purpose of the study was explained in English at the beginning of the online survey. The respondent was given the opportunity to ask questions via a dedicated email address. A waiver for signed consent was obtained because the survey presented no more than a minimal risk to participants and involved no procedures for which written consent is usually required outside the study context. To maximise confidentiality, personal identifiers were not required.
HCWs were screened for their awareness of any of the seven published vaccines. Notably, Pfizer announced during the study that the efficacy of their vaccine in the first interim analysis was more than 90%.32
Patient and public involvement
While this study did not have a direct patient or public involvement, its aim was directed at the HCWs’ perceptions about the acceptance of COVID-19 vaccines. However, these HCWs are in the frontline of the pandemic, serving to save the lives of thousands of patients worldwide. Therefore, safeguarding HCWs becomes among healthcare and patients’ priorities. No patients were directly involved in this research. The results of the study were published as a preprint that was shared with study participants.
Descriptive statistics approaches, with means and SDs, were applied to continuous variables, and percentages were used for dichotomous variables. The two-sample t-test was used to evaluate continuous scores, and the Z test was used to compare proportions.
A multivariable logistic regression model was used to explore associations between the outcome variable of HCW knowledge about the available COVID-19 vaccine candidates and HCW demographic, belief toward vaccine candidates, and level of anxiety. The association between predictors and the outcome was expressed as the OR and 95% CI. SPSS (V.21; IBM Corp) was used for the data analysis, Excel (Microsoft) was used for creating figures and depictions, and statistical significance was set at p=0.050.33
A total of 2007 HCWs agreed to participate, and 1512 participants (75.3%) completed the survey and were included in the analysis. Almost quarter of respondents did not complete the survey and were excluded from analysis. The participants’ sociodemographic characteristics are shown in table 1.
Women comprised most of the population (62.4%), most participants (70.3%) were between 21 and 40 years of age, 68.6% were married—though only 47.3% were living with their families—and 76.2% reported not having any chronic illnesses.
Respondents’ working areas were distributed almost evenly across different sectors of health institutions, but the majority were from the public/governmental (47.1%) sectors and tertiary institutions (62.2%). In terms of awareness of potential vaccine candidates reported in the literature, the majority (59.5%) reported knowing about at least one vaccine.
The ChAdOx1 nCoV-19 vaccine was the vaccine recognised the most by HCWs (39.3%), followed by the Gam-COVID-Vac vaccine (31.9%) and the RNA BNT162b2 vaccine (30.8%). The least well-known vaccine among HCWs was the mRNA-1273 vaccine (19.9%; table 2).
HCWs were asked to indicate their readiness to receive each type of COVID-19 vaccine with response categories of ‘never, maybe or sure’ (ie, willing to receive). The respondents reported ‘maybe’ in (65.1%) for the (AstraZeneca) vaccine and up to (75.5%) for the (Moderna), while they were ‘sure’ to receive the vaccine if it was (CanSino) in (9.3%) but up to (24.4%) if the (AstraZeneca) one, on the other hand they answered ‘never receive’ for the (Johnson and Johnson) or (Pfizer) vaccines in (10.2%) but up to (18.3%) for the (CanSino) (table 2).
In determining factors influencing differential readiness of HCWs to receive vaccine candidates, a multiple-response dichotomies analysis showed that respondents’ perception of the vaccine candidate as being more efficient in preventing infection was the most influencing factor (33%) in their decisions, followed by their personal preferences (29%) and the vaccine’s manufacturing country (28.6%). The least influential factors were media and social media coverage (12.3%) and trustworthiness (4.2%; table 3).
The HCW’s sources of information about COVID-19 vaccines are shown in table 4. The WHO website was the most used source for information (51.1%), followed by social media networks (48.3%), the Saudi Ministry of Health (MOH) website (43.8%) and official press releases (38.3%). The Centers for Disease Control and Prevention website was used by only one-third of participants (table 4).
A substantial number of HCWs in this study (n=612, 40.5%) reported unawareness of some vaccine candidates reported in scientific literature as of the time of the study. Therefore, as a secondary analysis, the generalised linear multivariate gamma regression analysis was used to explain the predictors of how likely the surveyed HCWs were to be aware of the different scientifically reported vaccine candidates. These results are presented in table 5 and show that women knew significantly less than men about the different vaccine candidates (p=0.016). Older age correlated significantly and positively with more knowledge (p=0.027). Also, physicians knew significantly more about vaccine candidates than other HCWs did (p=0.001), and the HCWs from primary and secondary health centres knew of significantly fewer COVID-19 vaccine candidates than did HCWs from tertiary medical centres (p=0.002 for primary, p=0.02 for secondary). The participant’s belief in the ability of COVID-19 vaccines to stop the pandemic predicted significantly higher knowledge of the available vaccine candidates (p=0.009). HCWs who did not interact with COVID-19-infected family members knew significantly less about the available vaccine candidates (p=0.018). Other specific worry/anxiety levels and beliefs were assessed, as reported in table 5.
Our analysis (figure 1) showed a significantly higher percentage rate of HCW readiness to receive any COVID-19 vaccine relative to the refusal rate after the Pfizer announcement compared with before it (χ2(1)4.56, p=0.032). In addition, the percentage of HCWs accepting to take the BNT162b2 vaccine increased from 18% to 25.1%, and proportion of those who stated they will never take the BNT162b2 vaccine dropped from 12% to 8.1% following Pfizer’s announcement (figure 2).
Since the beginning of the pandemic, an unprecedented global effort to develop a vaccine has been underway; research and development of different technologies have been applied for different vaccine candidates. The effort resulted in several types of vaccine candidates developed with various technologies, including adenovirus and RNA-based vaccines, all of which are novel and have not been developed for wide clinical use in other infectious diseases. Gaining knowledge of such new vaccines, with the rapid evolution of the development process, may be challenging: only 40% of study participants were aware of the ChAdOx1 nCoV-19 vaccine,5–9 11 34 35 and only one-third were aware of the BNT162b2, Gam-COVID-Vac and Ad26.COV2-S vaccines. Only a quarter of participants knew about the remaining vaccines. To our knowledge, data about HCW knowledge of vaccine candidates have not been published elsewhere.
The acceptance rate of COVID-19 vaccines is variable. In a global survey in 19 countries about the potential acceptance of a COVID-19 vaccine among the public, 71.5% reported they would very or somewhat likely agree to receive a vaccine; respondents from China gave the highest proportion of positive responses (631 (88.6%) of 712 respondents) and the lowest proportion of negative responses (5 (0.7%) of 712) when asked if they would take a proven, safe and effective vaccine. Respondents from Poland reported the highest proportion of negative responses (182 (27.3%) of 666), whereas Russian respondents gave the lowest proportion of positive responses (373 (54.9%) of 680). Data are available about other diseases with multiple vaccine types as well. In a parental survey on acceptance of an intranasal, live, attenuated influenza vaccine, 81% preferred this version compared with the injectable inactivated influenza vaccine.36 During the H1N1 pandemic, 50 of 161 HCWs (31.1%) were willing to take the 2009 H1N1 vaccine.37 In a cross-sectional survey conducted in Riyadh in 2019 on influenza vaccine uptake, results showed an acceptance rate of 71% with hesitancy attributed to concerns on adverse events in 50% of participants.38 It was also noted that people in the Middle East generally have low acceptance rate of COVID-19 vaccines and such acceptance was 23%–66%.29 39 40 However, no such acceptance rate has been evaluated among HCWs.41
It is interesting to note that, of all the HCW respondents asked about taking a COVID-19 vaccine, only 20% or 24% preferred to receive the AstraZeneca or the Pfizer vaccine, respectively. This low response to acceptance of any vaccine in development may indicate variability in the knowledge and understanding about the different vaccines. Vaccine knowledge is an area that needs more study to understand variables contributing to acceptance or rejection of each type of vaccine according to different development platforms used. This understanding would aid policymakers in the development of appropriate educational materials to boost confidence in various vaccine platforms.
Many factors affect the choice to receive vaccines. In this study, the top reason for choosing a vaccine was that the vaccine seems more effective at preventing infection (33%). A previous study found that 50% vaccine efficacy was associated with a 51% rate of acceptance.42
The manufacturing country was another reason given for accepting the vaccine (in 28.6% of respondents). This finding is similar to results from a US survey related to hypothetical vaccines. The surveyed individuals had lower acceptance of the vaccine if it originated from a country outside the USA.42 Other contributing factors, such as fewer adverse effects, were also reported in this study.42 Understanding these factors is important to build strategies for vaccine acceptance in any community. Strategies should address concerns, contributing factors and misconceptions.43 Trustworthiness was indicated by approximately 4% of the respondents as a factor in accepting a COVID-19 vaccine. This is quite different when compared with the general population in the USA, in which trust and perceptions of local COVID-19 vaccination norms were the strongest predictors of COVID-19 vaccine acceptance.44 The difference might be the fact that our study included only HCWs who may have better understanding of the disease and the vaccination. It is important to note that trust is an important modifiable element of any successful vaccine campaign. Trustworthiness was strongly associated with acceptance of a COVID-19 vaccine,45 and this factor was also related to acceptance of other vaccines, such as H1N1, SARS and MERS-CoV vaccines.25
The most-reported sources of information for HCWs were the WHO website and social networks (as expected in a pandemic). Previously, Alsubaie et al46 reported results from the same HCW population, which showed that hospital announcements and MOH official statements were more commonly sought for information about the MERS-CoV national outbreak. In the case of the general public, the source of knowledge and information about COVID-19 was official government social media and Twitter.47 And another study showed 85.8% of the public in Saudi Arabia used the internet and social media for information regarding COVID-19. In a study from the USA, 45%–66% of HCWs used social media as a source of information.48 49 These findings suggest that HCWs in Saudi Arabia use social networking sites differently than their US counterparts, which is important for other studies that look at social media and knowledge. Seeking knowledge from reliable sources about the pandemic and vaccinations could significantly impact the HCWs’ perceptions of vaccine acceptance.50 Misinformation about the COVID-19 vaccine was associated with decreased vaccination acceptance among those who would otherwise definitely vaccinate.51
It is interesting to note the differences in knowledge about vaccines by level of training. Physicians knew significantly more about vaccine candidates than other HCWs did (p=0.001) (table 5). Similarly, in a study from the USA, general COVID-19 knowledge among physicians was higher than other HCW, but non-physicians who work in healthcare did not have greater knowledge than the public.49 Noteworthy, HCWs working in tertiary and academic centres were more knowledgeable about various vaccine candidates compared with HCWs working in primary and secondary centres. This result may be explained by more scientific activity and educational campaigns typically associated with teaching hospitals. This increased knowledge was especially common among physicians in our study, like other studies; in a cross-sectional survey conducted in Italy among HCWs to assess their knowledge, attitudes, and practices about vaccinations, physicians and those who had received information about vaccinations from scientific journals, educational activities, or professional associations were more likely to have adequate knowledge.52 The knowledge differences identified between centres and types of providers highlight the importance of academic activities and keeping up to date with the scientific literature during the COVID-19 pandemic.
Remarkably, after the Pfizer and BioNTech announcement about the efficacy rate of BNT162b2, the HCWs in our study demonstrated significantly more willingness to undergo vaccination.32 This change was despite simultaneous negative news on some COVID-19 vaccination trials, such as the halting of clinical studies with the CoronaVac vaccine by the Brazilian national sanitary regulator (Anvisa) due to a serious adverse event.53 Vaccine acceptance is a multifactorial issue, but having positive COVID-19 vaccine trial results circulating in the news and social media for several days after the press release on the efficacy of BNT162b2 could improve the HCWs’ willingness to vaccinate.
This study has the limitation of being self-reported and survey based, so future observational studies on the HCWs’ actual acceptance of various COVID-19 vaccines are warranted. As a cross-sectional survey promoted on social media, it is not possible to calculate a response rate, and results may not be generalisable over time; therefore, further research is warranted. Another aspect is the national design that needs further research for external validity in other countries.
HCW awareness of the several COVID-19 candidate vaccines could improve perception and acceptance of vaccination. Reliable sources on vaccine efficiency could improve vaccine uptake, and healthcare authorities should use these sources to decrease vaccine hesitancy among frontline healthcare providers.
Data availability statement
Data are available upon reasonable request.
The institutional review board at the College of Medicine and King Saud University Medical City approved the study (approval #20/0065/IRB).
We thank all the healthcare workers who participated in this survey and all those in the COVID-19 front lines. We also thank hodhodata.com for their statistical analysis and support.
M-HT and MB contributed equally.
Contributors M-HT, MB, JAA-T, ZAM and FAlsohime were involved in conception, analysed the data and wrote the manuscript. AAlhuzaimi, AA-E, FAljamaan, BS, AAlrabiaah and NMA contributed to the study design; collected, analysed and interpreted data; and edited the manuscript. AAlhuzaimi, FSA-S, KA, AAlrabiaah, AAlaraj, AAlhaboob and SA supervised data collection, analysed data and edited the manuscript. AA-E, RH and AJ interpreted the data and wrote the manuscript. All authors reviewed and approved the final version of the manuscript.
Funding The authors are grateful to the Deanship of Scientific Research, King Saud University, for funding through the Vice Deanship of Scientific Research Chairs. Award/grant number is not applicable.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.